Clinical Trial Update: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

Phase 2 study to assess tolerability of ianalumab (VAY736) with investigator's choice thrombopoietin receptor agonist in patients with primary immune thrombocyt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Evans Syndrome
• Immune Thrombocytopenia

Drugs mentioned

• Ianalumab (VAY736) (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) | Phase 2 | Status: NOT_YET_RECRUITING